The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa
Open accessAbstract
Cefiderocol (S-649266) is a novel parenteral siderophore cephalosporin conjugated with a catechol moiety at the third-position side chain. The in vitro activity of cefiderocol against Pseudomonas aeruginosa was enhanced under iron-depleted conditions, whereas that of ceftazidime was not affected. The monitoring of [thiazole- 14 C]cefiderocol revealed the increased intracellular accumulation of cefiderocol in P. aeruginosa cells incubated under iron-depleted conditions compared with those incubated under iron-sufficient conditions. Cefiderocol was shown to have potent chelating activity with ferric iron, and extracellular iron was efficiently transported into P. aeruginosa cells in the presence of cefiderocol as well as siderophores, while enhanced transport of extracellular ferric iron was not observed when one of the hydroxyl groups of the catechol moiety of cefiderocol was replaced with a methoxy group. We conclude that cefiderocol forms a chelating complex with iron, which is actively transported into P. aeruginosa cells via iron transporters, resulting in potent antibacterial activity of cefiderocol against P. aeruginosa .
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Apart from binding their primary ligand, FeEnt, with high affinity, and its aposiderophore Ent with 100-200-fold lower affinity (38), KpnFepA_1658, KpnIroN, and KpnFepA_4984 showed different preferences for ferric catecholate complexes and siderophore antibiotics cefiderocol [FeFDC (40,41)] and FeMB-1 (42,43):”
From Siderophore-mediated iron acquisition by Klebsiella pneumoniae (2024) · cites this paper as [40]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
ACETYLORNITHINASE OF ESCHERICHIA COLI: PARTIAL PURIFICATION AND SOME PROPERTIES
Vogel, H. J., & Bonner, D. M. (1956) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)65874-0 · Cited by 4,001
Metallo-β-Lactamases: the Quiet before the Storm?
Walsh, T. R., Toleman, M. A., Poirel, L., & Nordmann, P. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.2.306-325.2005 · Cited by 1,457
Comprehensive transposon mutant library of Pseudomonas aeruginosa
Jacobs, M. A., Alwood, A., Thaipisuttikul, I., Spencer, D. H., Haugen, E., Ernst, S., Will, O., Kaul, R., Raymond, C. K., Levy, R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2036282100 · Cited by 1,129
Woodford, N., Turton, J. F., & Livermore, D. M. (2011) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2011.00268.x · Cited by 881
Pseudomonas aeruginosa – a phenomenon of bacterial resistance
Strateva, T., & Yordanov, D. (2009) · Journal of Medical Microbiology · doi:10.1099/jmm.0.009142-0 · Cited by 803
Mechanisms of Multidrug Resistance in Acinetobacter Species and Pseudomonas aeruginosa
Bonomo, R. A., & Szabó, D. (2006) · Clinical Infectious Diseases · doi:10.1086/504477 · Cited by 751
Current Epidemiology and Growing Resistance of Gram-Negative Pathogens
Livermore, D. M. (2012) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2012.27.2.128 · Cited by 425
“Stormy waters ahead”: global emergence of carbapenemases
Patel, G., & Bonomo, R. A. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00048 · Cited by 423
Of Pseudomonas, porins, pumps and carbapenems
Livermore, D. M. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.3.247 · Cited by 393
Flagged first, then by citations
Research works printed but not linked: 4
- Griffiths E. 1978. Iron in biological systems, p 1–27. In Bullen JJ, Griffiths E (ed), Iron and infection. John Wiley & Sons, New York, NY.
- Nakamura R, Toba S, Tsuji M, Yamano Y, Shimada J. 2014. S-649266, a novel siderophore cephalosporin. IV: in vivo efficacy in various murine infection models, abstr F1-1558. Abstr 54th Intersci Conf Antimicrob Agents Chemother, American Society for Microbiology, Washington, DC.
- Nakamura R, Toba S, Ito A, Tsuji M, Yamano Y, Shimada J. 2014. S-649266, a novel siderophore cephalosporin. V: pharmacodynamic assessment in murine thigh infection models, abstr F1-1559. Abstr 54th Intersci Conf Antimicrob Agents Chemother, American Society for Microbiology, Washington, DC.
- Müller C, Hofer B, Desarbre E, Page MGP. 2010. Enhanced activity of the siderophore monosulfactam BAL30072 (BAL) against Acinetobacter in iron-limited conditions, abstr F1-2133. Abstr 50th Intersci Conf Antimicrob Agents Chemother, American Society for Microbiology, Washington, DC.
Cited by
Sorted by citations
Items 301–357 of 357
Mallecot, E., Berti, V., Petitjean, M., Meyer, J., Gueye, S., Morel‐Journel, T., Timsit, S., Clermont, O., Poirel, L., Denamur, É., et al. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01679-25 · Cited by 1
Ritiu, S. A., Băloi, A., Păpurică, M., Săndesc, D., Toma, D., Barsac, C. R., Popovici, S. E., Butaș, M., Botoaca, A.-M., & Bedreag, O. H. (2026) · Pathogens · doi:10.3390/pathogens15080786 · Cited by 1
Discovery of a New Siderophore Cephalosporin, Cefiderocol
Yamano, Y. (2024) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.23-00197-1 · Cited by 1
Self-citationEzquer, C., Ferriols‐Lisart, R., Almiñana, M. A., Carbonell, J., Hurtado, L., García‐Vargas, L., & Aguilar, G. (2025) · Biomedical Chromatography · doi:10.1002/bmc.70104 · Cited by 1
Newer Antibiotic Agents in Pipeline
Khan, I. A. (2022) · Springer eBooks · doi:10.1007/978-981-16-9097-6_18 · Cited by 1
Treatment of MDR Gram-Negative Bacteria Infections: Ongoing and Prospective
Sharma, M. K., Rizvan, M., Ahmad, N., Jain, P., & Kumar, M. (2022) · Journal of Pure and Applied Microbiology · doi:10.22207/jpam.16.3.65 · Cited by 1
Hogan, A. M., Natarajan, A., Maydaniuk, D. T., Léon, B., Batun, Z., Motnenko, A., Palacios, A., Bosch, A., & Cardona, S. T. (2022) · doi:10.1101/2022.11.01.510852 · Cited by 1
Cefiderocol bei AML-Patientin mit neutropenischem Infekt durch 4MRGN Klebsiella pneumoniae (VIM-1)
Urmann, E., Stamm, P., & Wißkirchen, J. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1975-2594
Mehringer, L., Seybold, U., & Zöller, M. (2023) · Die Anaesthesiologie · doi:10.1007/s00101-023-01252-w
Anti Bacterial Drugs: A Bright Past but a Challenging Future
Kalia, N. P., Kumar, M., Khodor, S. A., & Sharma, S. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815080056123020007
Bir İlaç Monografı; Sefiderokol
Kars, B., Öztaş, S., & Altındiş, M. (2023) · JOURNAL OF BIOTECHNOLOGY AND STRATEGIC HEALTH RESEARCH · doi:10.34084/bshr.1279754
Naber, K. G., Johansen, T. E. B., & Wagenlehner, F. R. A. (2024) · Springer eBooks · doi:10.1007/978-3-319-92366-6_6
Rajapaksha, N., & Rivera, M. (2024) · Encyclopedia of Inorganic and Bioinorganic Chemistry · doi:10.1002/9781119951438.eibc2864
Lewis, J. S., & Bush, K. (2023) · ClinMicroNow · doi:10.1002/9781683674849.mcm0071
Lewis, J. S., & Bush, K. (2023) · ClinMicroNow · doi:10.1002/9781683670438.mcm0071
The Fight for Iron: A Central Theme in Host-Pathogen Interactions
Hamad, M. A. (2025) · Springer eBooks · doi:10.1007/978-981-96-1305-2_11
Current challenges and advances on Infectious Diseases in Solid Organ Transplantation
(2025) · Frontiers Media SA eBooks · doi:10.3389/978-2-8325-6011-2
Takemura, M. (2025) · Folia Pharmacologica Japonica · doi:10.1254/fpj.24082
Epifanova, N. Y. (2025) · Podderživaûŝaâ terapiâ v onkologii. · doi:10.17650/3034-2473-2025-2-2-44-60
Jean-Pierre, V., Sorlin, P., Pantel, A., Chiron, R., Lavigne, J.-P., Jeannot, K., & Marchandin, H. (2024) · Figshare · doi:10.6084/m9.figshare.26735328
Jean-Pierre, V., Sorlin, P., Pantel, A., Chiron, R., Lavigne, J.-P., Jeannot, K., & Marchandin, H. (2024) · Figshare · doi:10.6084/m9.figshare.26735325
Ota, K., Kaku, N., Mitsumoto‐Kaseida, F., Uno, N., Kosai, K., Takazono, T., Hasegawa, H., Sakamoto, K., Morinaga, Y., Izumikawa, K., et al. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.02568-25
Aoyagi, T. (2026) · Kansenshogaku zasshi · doi:10.11150/kansenshogakuzasshi.r25002
An immune-mediated effect of the antibiotic cefiderocol on LPS-induced acute lung injury
Hao, M., Li, Y., Bi, Y., Liu, S., & Ju, M. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01634-25
Varnado, A., Moheb, S., Sanchez, S. D., Rodriguez, C., Hamza, M., Escalante, J., Tuttobene, M. R., Traglia, G. M., Pasterán, F. G., Tolmasky, M. E., et al. (2026) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2026.107781
Merrick, C. E., Patel, K. D., Gulati, N. M., Gulick, A. M., & Wencewicz, T. A. (2026) · ChemRxiv · doi:10.26434/chemrxiv.15001453/v1
Merrick, C. E., Patel, K. D., Gulati, N. M., Gulick, A. M., & Wencewicz, T. A. (2026) · ChemRxiv · doi:10.26434/chemrxiv.15001453/v2
Structure-function studies of β-lactamases
Zavala, A. J. (2018) · doi:10.70675/091a31c9z459fz4029z8a0fzcd7f81d42f9b
Lascols, C. (2024) · theses.fr (ABES) · doi:10.70675/8f7bbeb6z0d6cz4e67z9e53zcdacdc0bdd2b
Lombardi, A., Mangioni, D., Viero, G., Alagna, L., Renisi, G., Saltini, P., & Bandera, A. (2026) · Transplant International · doi:10.3389/ti.2026.15264
Lee, H., Kim, S. O., You, S., Segalina, A., Noh, T., & Ihee, H. (2026) · Nature Communications · doi:10.1038/s41467-026-72127-y
Turowski, P., Cremanns, M., Pfennigwerth, N., & Gatermann, S. G. (2026) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkag193
Kang, S., Lee, S.-A., Choi, S., Park, Y., & Kim, D. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110104
Sung, Y. H., Park, S. M., Lee, H. J., & Yoon, Y. K. (2026) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2026.06.023
Organ Perfusion: Time As a Therapeutic Ally
(2026) · Frontiers Media SA eBooks · doi:10.3389/978-2-8325-8109-4
Estabrook, M., Suzuki, E., Shimizu, A., & Okade, H. (2026) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlag166
Volck, F., Revillot-Schmidt, A.-E., Hubert, T., Crespin, V., Mislin, G. L. A., Cunrath, O., Madec, M., & Schalk, I. J. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2602150123
Turowski, P., Pfennigwerth, N., & Gatermann, S. G. (2026) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlag178
Ding, C., Li, X., Wu, Y., Wang, J., Wang, S., Wang, Y., & Ding, L. (2026) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2026.117725
Liu, R., Miller, P. A., & Miller, M. J. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118805
Auranofin shows bactericidal activity in Pseudomonas aeruginosa by targeting thiol homeostasisPreprint
Lüscher, A., Mattenberger, Y., Falconnet, L., Civic, N., van Delden, C., & Köhler, T. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.11.750932
Kimishima, A., Suzuki, R., Kamo, T., Wasuwanich, P., Matsui, H., Negami, S., Honma, S., Ujie, Y., Kondo, N., Hanaki, H., et al. (2026) · ChemMedChem · doi:10.1002/cmdc.70498
Clinical Development of Antibacterial Drugs: Recent Progress and Future Outlook
Kathayat, D., Vidovszky, A., Khan, Y., Denk, A., Paudel, A., Verma, A., Helmy, Y. A., & Rajashekara, G. (2026) · Antibiotics · doi:10.3390/antibiotics15100993
Warecki, B. A., Parodi, C., Romero, F. D., González, L. J., & Vila, A. J. (2026) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.6c00699
Zhong, L., Wang, C., Wang, S., Zhang, H., Kao, R. Y. T., Toy, P. H., Ho, P., Li, H., & Sun, H. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c02268
Meroi, M., Polo, J. A. D. C., Scardellato, R., Nazeri, A., Savoldi, A., Costa, R. D., Piddock, L. J. V., Cohn, J., Tacconelli, E., Morra, M., et al. (2026) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2026.09.016
Optimizing cefiderocol use in clinical practice
Sharara, S. L., Hsu, A. J., Simner, P. J., & Tamma, P. D. (2026) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000001243
Mojica, M. F., Zeiser, E. T., Becka, S. A., Caverly, L. J., Lipuma, J. J., Bonomo, R. A., & Papp‐Wallace, K. M. (2026) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkag347
Stracquadanio, S., Nicolosi, A., Privitera, G. F., Bongiorno, D., Calvo, M., Migliorisi, G., Barone, T., Perez, M., Marra, G., Fasciana, T., et al. (2026) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2026.108044
Shinya-Hidalgo, M., Martínez, J. R. W., Squella, S., García, P., Alcalde‐Rico, M., Munita, J. M., & Wozniak, A. (2026) · Antibiotics · doi:10.3390/antibiotics15111085
Metadata
- Authors
- Ito, A., Nishikawa, T., Matsumoto, S., Yoshizawa, H., Sato, T., Nakamura, R., Tsuji, M., & Yamano, Y.
- Affiliations
- Shionogi (Japan) (JP)
- Corresponding author
- Ito, Akinobu
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2016-12
- Volume
- 60
- Issue
- 12
- Pages
- 7396-7401
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC5119021
- OpenAlex
- W2530661320
- Cited by
- 352
- References
- 33
- Citations by year
- 2026: 52 · 2025: 34 · 2024: 35 · 2023: 37 · 2022: 40 · 2021: 37 · 2020: 41 · 2019: 29 · 2018: 30 · 2017: 16 · 2016: 1
- FWCI
- 12.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- cefiderocol, siderophore cephalosporin, Pseudomonas aeruginosa, iron chelation, catechol moiety, iron depletion, intracellular accumulation, iron transporters, antibacterial activity, ceftazidime
- MeSH terms
- Cefiderocol, Anti-Bacterial Agents, Biological Transport, Carbon Radioisotopes, Ceftazidime, Cephalosporins, Fluoresceins, Fluorescent Dyes, Iron, Iron Chelating Agents, Microbial Sensitivity Tests, Pseudomonas aeruginosa, Structure-Activity Relationship, Thiazoles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
